Fluvoxamine treatment and D2 receptors

A pet study on OCD drug-naïve patients

Rosa Maria Moresco, Lucia Pietra, Marta Henin, Andrea Panzacchi, Marco Locatelli, Lorena Bonaldi, Assunta Carpinelli, Clara Gobbo, Laura Bellodi, Daniela Perani, Ferruccio Fazio

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naíve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-naíve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalNeuropsychopharmacology
Volume32
Issue number1
DOIs
Publication statusPublished - Jan 1 2007

Fingerprint

Fluvoxamine
Obsessive-Compulsive Disorder
Pets
Pharmaceutical Preparations
Basal Ganglia
Therapeutics
Raclopride
Putamen
Major Depressive Disorder
Serotonin Uptake Inhibitors
Diagnostic and Statistical Manual of Mental Disorders
Positron-Emission Tomography
Antidepressive Agents
Healthy Volunteers
Age Groups
Brain

Keywords

  • Antidepressant
  • Dopamine receptor
  • Drug naïve
  • Emission tomography
  • Molecular imaging
  • Obsessive-compulsive disorder

ASJC Scopus subject areas

  • Pharmacology

Cite this

Moresco, R. M., Pietra, L., Henin, M., Panzacchi, A., Locatelli, M., Bonaldi, L., ... Fazio, F. (2007). Fluvoxamine treatment and D2 receptors: A pet study on OCD drug-naïve patients. Neuropsychopharmacology, 32(1), 197-205. https://doi.org/10.1038/sj.npp.1301199

Fluvoxamine treatment and D2 receptors : A pet study on OCD drug-naïve patients. / Moresco, Rosa Maria; Pietra, Lucia; Henin, Marta; Panzacchi, Andrea; Locatelli, Marco; Bonaldi, Lorena; Carpinelli, Assunta; Gobbo, Clara; Bellodi, Laura; Perani, Daniela; Fazio, Ferruccio.

In: Neuropsychopharmacology, Vol. 32, No. 1, 01.01.2007, p. 197-205.

Research output: Contribution to journalArticle

Moresco, RM, Pietra, L, Henin, M, Panzacchi, A, Locatelli, M, Bonaldi, L, Carpinelli, A, Gobbo, C, Bellodi, L, Perani, D & Fazio, F 2007, 'Fluvoxamine treatment and D2 receptors: A pet study on OCD drug-naïve patients', Neuropsychopharmacology, vol. 32, no. 1, pp. 197-205. https://doi.org/10.1038/sj.npp.1301199
Moresco RM, Pietra L, Henin M, Panzacchi A, Locatelli M, Bonaldi L et al. Fluvoxamine treatment and D2 receptors: A pet study on OCD drug-naïve patients. Neuropsychopharmacology. 2007 Jan 1;32(1):197-205. https://doi.org/10.1038/sj.npp.1301199
Moresco, Rosa Maria ; Pietra, Lucia ; Henin, Marta ; Panzacchi, Andrea ; Locatelli, Marco ; Bonaldi, Lorena ; Carpinelli, Assunta ; Gobbo, Clara ; Bellodi, Laura ; Perani, Daniela ; Fazio, Ferruccio. / Fluvoxamine treatment and D2 receptors : A pet study on OCD drug-naïve patients. In: Neuropsychopharmacology. 2007 ; Vol. 32, No. 1. pp. 197-205.
@article{7d6c6c63b44d4a9ea57c2f0848b01a54,
title = "Fluvoxamine treatment and D2 receptors: A pet study on OCD drug-na{\"i}ve patients",
abstract = "Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD na{\'i}ve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3{\%} in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-na{\'i}ve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.",
keywords = "Antidepressant, Dopamine receptor, Drug na{\"i}ve, Emission tomography, Molecular imaging, Obsessive-compulsive disorder",
author = "Moresco, {Rosa Maria} and Lucia Pietra and Marta Henin and Andrea Panzacchi and Marco Locatelli and Lorena Bonaldi and Assunta Carpinelli and Clara Gobbo and Laura Bellodi and Daniela Perani and Ferruccio Fazio",
year = "2007",
month = "1",
day = "1",
doi = "10.1038/sj.npp.1301199",
language = "English",
volume = "32",
pages = "197--205",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Fluvoxamine treatment and D2 receptors

T2 - A pet study on OCD drug-naïve patients

AU - Moresco, Rosa Maria

AU - Pietra, Lucia

AU - Henin, Marta

AU - Panzacchi, Andrea

AU - Locatelli, Marco

AU - Bonaldi, Lorena

AU - Carpinelli, Assunta

AU - Gobbo, Clara

AU - Bellodi, Laura

AU - Perani, Daniela

AU - Fazio, Ferruccio

PY - 2007/1/1

Y1 - 2007/1/1

N2 - Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naíve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-naíve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.

AB - Changes in D2 receptors during antidepressant therapy have been reported in patients with major depressive disorder using PET/SPET. The aim of this study was to evaluate modifications in D2 receptors that might occur in patients affected by obsessive-compulsive disorder (OCD) during serotonin reuptake sites inhibitors (SSRIs). To this purpose, we measured the in vivo binding of [11C]raclopride ([11C]Rac)in the brain of a group of OCD naíve patients before and after the repeated administration of the inhibitor SSRI fluvoxamine. Eight patients with a Diagnostic and Statistical Manual of Mental Disorders IVth edition diagnosis of OCD completed the study undergoing a PET scan and a complete clinical evaluation before and during treatment with fluvoxamine. Patients have been compared also with a group of nine age-matched normal volunteers. Fluvoxamine treatment significantly improved clinical symptoms and increased [11C]Rac binding potential (BP) in the basal ganglia of OCD patients (7.5±5.2, 6.9±6.9, and 9.9±9.3% in dorsal caudate, dorsal putamen, and ventral basal ganglia, respectively; p11C]Rac BP of previously drug-naíve OCD patients. The modifications in D2 receptor availability might be secondary to fluvoxamine effects on serotoninergic activity.

KW - Antidepressant

KW - Dopamine receptor

KW - Drug naïve

KW - Emission tomography

KW - Molecular imaging

KW - Obsessive-compulsive disorder

UR - http://www.scopus.com/inward/record.url?scp=33845686605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845686605&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301199

DO - 10.1038/sj.npp.1301199

M3 - Article

VL - 32

SP - 197

EP - 205

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 1

ER -